Raed Attia

Venture Partner

Mikel Badiola

Venture Partner

Jingjing Chai

General Partner

Gray Chen

Co-Founding Partner and Venture Partner

Xiuya Gang

Venture Partner

Hongkai He

General Partner

Ricki Huang

Venture Partner

Junyuan Jiang

Venture Partner

Diana Liu

Venture Partner

Fawaz Shawwa

Venture Partner

Tianmeng Xu

Founding Partner

Tianyi Yu

General Partner

Haolin Zhang

Venture Partner

Huiliang Wang Ph.D

Venture Partner

Xudong Lv Ph.D

Venture Partner

14 past transactions

Finwave

Venture Round in 2022
Finwave Semiconductor specializes in the development of advanced gallium nitride (GaN) transistors and integrated circuits (ICs) tailored for 5G communications and power conversion applications. The company utilizes a unique 3DGaN technology, specifically its differentiated fin field-effect transistor (FinFET) design, to enhance the performance of high-volume applications such as radio frequency front end (RFFE) systems for mobile devices. This innovative approach allows Finwave to create semiconductor materials with distinct properties, contributing to advancements in electronics and energy management.

Aspecta

Seed Round in 2022
Aspecta.ai provides a talent engine platform whose recruiting modules are powered by artificial intelligence technology, which integrates big web talent data and analyzes millions of coding projects, tech posts, patents, and papers.

Regenerative Bio

Angel Round in 2022
Regenerative Bio is a pioneering biotechnology company focused on anti-aging solutions through the integration of artificial intelligence and advanced computing technologies. The company is dedicated to researching and developing ingredients, formulations, and therapies aimed at mitigating the effects of aging and enhancing overall health. By leveraging AI, quantum physics, and high-throughput preparation methods, Regenerative Bio seeks to improve cellular health and energy metabolism, ultimately promoting longer, healthier lives. Their innovative approach combines pharmaceutical technology with biological research, addressing age-related health issues and contributing to the field of longevity science.

Snaplii

Series A in 2021
Snaplii is a digital wallet focused on transforming the North American fintech landscape by offering a comprehensive payment solution. The platform provides a range of services, including payment processing, lending, and card issuance, designed to enhance user experience. Snaplii features self-issued closed-loop digital credit cards that facilitate traditional payment functions while integrating innovative financial tools. This approach aims to assist merchants in increasing customer engagement and boosting sales through a unique membership and marketing program. By combining these functionalities, Snaplii positions itself as a valuable partner for businesses looking to drive traffic and improve consumer interaction.

EasyTransfer

Series C in 2021
Beijing Easy Transfer Commercial Service Co., Ltd. operates an online platform designed to facilitate international tuition payments for students studying abroad. Established in 2013 and headquartered in Beijing, the company caters to students, their families, and educational institutions by simplifying the payment process for tuition fees and dormitory rents at numerous global colleges and universities. Easy Transfer has formed partnerships with various payment processors and prominent Chinese banks to enhance its service offerings. The platform allows for seamless cross-border money transfers, ensuring that international students can efficiently send and receive funds. Easy Transfer has garnered support from several investment groups, affirming its position as a leading financial service provider in the international education sector.

Cardea

Series A in 2021
Cardea Bio, Inc. is a biotechnology company based in San Diego, California, specializing in bioelectronics and graphene-based digital biosensor technology. Founded in 2013, the company develops products that facilitate precision healthcare by enhancing the ease, speed, and cost-effectiveness of diagnostics. Its key offerings include AGILE R100, an innovative assay for small molecule drug discovery, and AGILE R200, an automated high-throughput screening solution. Cardea's biosensors utilize biocompatible graphene to transform biological signals into digital data, enabling real-time analysis of biomolecules. This technology supports applications in small molecule validation, antibody characterization, and biomolecular analysis, serving the life sciences and healthcare sectors. The company also sells its products online, contributing to advancements in research and diagnostics.

Manus Bio

Series B in 2020
Manus Bio Inc. recreates plant processes in microorganisms to produce natural ingredients through fermentation. The company’s microbial platform converts sugar sources into ingredients with applications, such as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. It merges metabolic engineering, protein engineering, and systems biology technologies to generate microbes that produce various plant-based ingredients. The company has a strategic partnership with BBGI Public Company Limited. Manus Bio Inc. was formerly known as Manus Biosynthesis, Inc. and changed its name to Manus Bio Inc. in June 2018. The company was founded in 2011 and is based in Cambridge, Massachusetts. It has manufacturing facilities in Cambridge, Massachusetts; and Augusta, Georgia.

Manus Bio

Series B in 2020
Manus Bio Inc. recreates plant processes in microorganisms to produce natural ingredients through fermentation. The company’s microbial platform converts sugar sources into ingredients with applications, such as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. It merges metabolic engineering, protein engineering, and systems biology technologies to generate microbes that produce various plant-based ingredients. The company has a strategic partnership with BBGI Public Company Limited. Manus Bio Inc. was formerly known as Manus Biosynthesis, Inc. and changed its name to Manus Bio Inc. in June 2018. The company was founded in 2011 and is based in Cambridge, Massachusetts. It has manufacturing facilities in Cambridge, Massachusetts; and Augusta, Georgia.

Pointcloud

Seed Round in 2020
Pointcloud is a developer of a 3D imaging platform on a chip. The company offers a technology for big data analytics on 3D point clouds based on machine learning. It enables the future of augmented reality, robotics, and autonomous mobility.

Butlr

Seed Round in 2020
Butlr Technologies Inc. develops a wireless sensor system that captures and transmits real-time data on human movement and behavior in various environments, particularly in retail and hospitality. Founded in 2019 and based in Burlingame, California, Butlr's technology combines proprietary hardware with advanced artificial intelligence to analyze location and duration data, translating it into insights about consumer preferences and behaviors. The company's low-cost thermal imaging system gained attention during the coronavirus pandemic as a tool to protect the health of employees and customers. Unlike traditional cameras, Butlr's sensors detect unique biometric heat signatures, allowing for privacy-preserving monitoring while enabling businesses to optimize their spaces. This technology has broader implications, with a vision for responsive architecture that adapts environments based on real-time data, potentially enhancing urban infrastructure by predicting and responding to dynamic conditions such as pedestrian traffic and weather changes.

Cardea

Series A in 2020
Cardea Bio, Inc. is a biotechnology company based in San Diego, California, specializing in bioelectronics and graphene-based digital biosensor technology. Founded in 2013, the company develops products that facilitate precision healthcare by enhancing the ease, speed, and cost-effectiveness of diagnostics. Its key offerings include AGILE R100, an innovative assay for small molecule drug discovery, and AGILE R200, an automated high-throughput screening solution. Cardea's biosensors utilize biocompatible graphene to transform biological signals into digital data, enabling real-time analysis of biomolecules. This technology supports applications in small molecule validation, antibody characterization, and biomolecular analysis, serving the life sciences and healthcare sectors. The company also sells its products online, contributing to advancements in research and diagnostics.

Kula Bio

Seed Round in 2020
Kula Bio, Inc. is focused on developing innovative biological solutions for modern agriculture. Founded in 2018 and based in Somerville, Massachusetts, the company specializes in the production of organic biofertilizers using nitrogen-fixing microbes charged with renewable energy. By enhancing natural microbial processes, Kula Bio aims to create affordable and sustainable fertilization methods that enable farmers to increase their yields while promoting environmental stewardship. The company's approach seeks to disrupt traditional synthetic fertilizers, bridging the gap between effective agricultural practices and the responsible management of natural resources.

Lightelligence

Venture Round in 2020
Lightelligence builds optical chips that offer orders of magnitude improvement in terms of high speed, low latency, and low power consumption compared to traditional electronic architectures.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.